Navigation Links
Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
Date:8/7/2008

g sales growth in this product in the second half of 2008 while we remain the only generic available on the U.S. market. Our SEASONIQUE(R) extended-cycle oral contraceptive and the PARAGARD(R) IUC were the principal drivers in higher proprietary product sales year-over-year."

"The strength of our generic and proprietary product portfolios, our commercial strength in important global markets, and our focus on delivering sound results are among the benefits that make the proposed acquisition of Barr by Teva, announced on July 18th, so attractive. Management is committed to continuing to deliver strong performance as the acquisition process progresses, to ensure that at the close of the transaction, the capabilities of Barr will significantly complement Teva's existing business," Downey continued.

Revenues

Generic Product Sales

The Company's generic product sales were $557 million for the second quarter of 2008, compared to $484 million in the prior year period. For the first six months of 2008, generic product sales were $1.0 billion, compared to $956 million for the prior year period. A discussion of the Company's generic product sales for the second quarter of 2008 compared to the prior year period is presented below.

North American

Sales of North American generic products totaled $340 million for the

second quarter of 2008, compared to $296 million in the prior year period.

The increase in sales is primarily related to higher sales of generic oral

contraceptives.

Sales of generic oral contraceptives increased 34% to $155 million in the

second quarter of 2008, up from $116 million in the prior year period.

The increase primarily reflects sales of Ocella(TM), the Company's generic

Yasmin(R) oral contraceptive product that was launched at the end of the

second quarter of 2008, which more than offset lower volume and pricing on

several other oral contraceptive
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
2. Caliper Life Sciences Reports Second Quarter 2008 Results
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. EntreMed Reports Second Quarter 2008 Financial Results
5. Transgenomic Reports Second Quarter 2008 Results
6. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
7. Bionovo Reports Second Quarter 2008 Financial Results
8. AtriCure Reports Record Second Quarter 2008 Financial Results
9. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
10. eResearchTechnology Reports Second Quarter 2008 Results
11. SuperGen Reports 2008 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... DALLAS , May 22, 2015 ... Market by Product (1D & 2D Gel Electrophoresis, Agarose ... CGE, MEKC, Reagents, Informatics), by Application & by End ... the Electrophoresis Market is expected to reach around $1.98 ... the forecast period 2015 to 2020. ...
(Date:5/22/2015)... May 22, 2015 Knowledgent , ... paper that explores the potential of big data analytics ... paper was developed to help life sciences and healthcare ... data to gain critical business insights. , The life ... of data driven by patient profiling, compliance and regulatory ...
(Date:5/21/2015)... - SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: ... commercializes proprietary technologies and products for advanced microarray diagnostics, ... second fiscal quarter ended March 31, 2015. ... business with our existing customers and to develop new ... of SQI. "The delivery of a fully automated sqidlite™ ...
(Date:5/21/2015)... N.J. (PRWEB) May 21, 2015 ... circulation audit and been admitted to BPA Worldwide ... BPA Worldwide will track audience data for Specialty ... coverage. , “By becoming a member of ... dedication to providing our clients with the most ...
Breaking Biology Technology:Electrophoresis Market Worth $1.98 Billion by 2020 2Electrophoresis Market Worth $1.98 Billion by 2020 3Electrophoresis Market Worth $1.98 Billion by 2020 4New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2
... ZURICH, Switzerland, November 4, 2011 Major ... in the treatment of patients with refractory ascites due ... University of Vienna and Vienna General Hospital (AKH Wien) ... the ALFApump System were performed at Vienna General Hospital ...
... Nov. 3, 2011 Cumberland Pharmaceuticals Inc. (NASDAQ: ... hospital acute care and gastroenterology markets, today announced third quarter ... the three months ended September 30, 2011, net revenue was ... period. The growth in net revenue was driven by an ...
... AUSTIN, Texas, Nov. 3, 2011 Vermillion, ... diagnostics company, has received a notice of allowance from the ... covering a combination of biomarkers that could be used in ... raises the risk of heart attack and stroke. ...
Cached Biology Technology:The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 2Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 3Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 4Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 5Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 6Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 7Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 8Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 9Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 10Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 11Cumberland Pharmaceuticals Reports Third Quarter 2011 Financial Results 12Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease 2Vermillion Receives Notice of Allowance for 5th Biomarker Patent Related to Peripheral Artery Disease 3
(Date:4/27/2015)... ATLANTA , April 27, 2015  For more ... and trade show has been the premier worldwide event ... Systems 2015 is a must-attend event for any local, ... insight into the emerging commercial markets and current applications ... and innovations of this projected $48 billion industry, and ...
(Date:4/20/2015)... The announcement comes as demand for fire vault ... Ireland,s foremost records management company, has secured ... impressive track record of clients within the first 12 months, ... sector in Dubai . As a result, ... a further eight staff members at its Irish headquarters. The ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
Breaking Biology News(10 mins):UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 2UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 3UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 4UNMANNED SYSTEMS 2015: Largest International Conference and Trade Show for the Drone and Unmanned Technology Industry 5Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3
... The University of Chicago Celiac Disease Center is hosting ... 22-25, 2013 in Chicago. The symposium is the largest ... The meeting, which follows the 2011 conference in Oslo, ... United States since 2006. The Chicago meeting seeks ...
... Paris, France, dedicated to improving human health through international ... grant award to a new global research network of ... Research Center at Icahn School of Medicine at Mount ... as part of the Fondation Leducq,s Transatlantic Networks of ...
... in a wide range of problems from arthritis to cardiovascular ... temper this problem. A new research report appearing in the ... , helps explain why DHA is important in reducing inflammation, ... will help bring people back to optimal health. Specifically, researchers ...
Cached Biology News:UChicago Celiac Disease Center to host international symposium 2Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 2Fondation Leducq awards $6 million grant for global research network for cardiac regeneration 3Harvard and USC scientists show how DHA resolves inflammation 2
Vascular Endothelial Growth Factor C Class: Antibody Product Group: Angiogensis...
Tropomyosin 4 [Tm4]...
Phospho-MEF2A(Thr312)...
Mouse monoclonal [2A4] to Cytokeratin 8 + 18 + 19 ( Abpromise for all tested applications). Antigen: Cytokeratins isolated from cultured pig kidney epithelial cells. Entrez GeneID: 3856 S...
Biology Products: